These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21554259)

  • 1. The clinical management of tumour lysis syndrome in haematological malignancies.
    Will A; Tholouli E
    Br J Haematol; 2011 Jul; 154(1):3-13. PubMed ID: 21554259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour lysis syndrome: new therapeutic strategies and classification.
    Cairo MS; Bishop M
    Br J Haematol; 2004 Oct; 127(1):3-11. PubMed ID: 15384972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
    Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
    Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor lysis syndrome.
    Jeha S
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):4-8. PubMed ID: 11694945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour lysis syndrome.
    Calvo Villas JM
    Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the management of malignancy-associated hyperuricaemia.
    Mahmoud HH; Leverger G; Patte C; Harvey E; Lascombes F
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):18-20. PubMed ID: 9647616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor lysis syndrome: a systematic review of case series and case reports.
    Firwana BM; Hasan R; Hasan N; Alahdab F; Alnahhas I; Hasan S; Varon J
    Postgrad Med; 2012 Mar; 124(2):92-101. PubMed ID: 22437219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological emergencies: tumor lysis syndrome.
    Sobota J; Püsküllüoglu M; Zygulska AL
    Przegl Lek; 2014; 71(4):210-4. PubMed ID: 25141580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome.
    Ito S; Fujiwara SI; Yoshizawa T; Hayatsu K; Sekiguchi K; Murahashi R; Nakashima H; Matsuoka S; Ikeda T; Toda Y; Kawaguchi S; Nagayama T; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Ashizawa M; Yamamoto C; Hatano K; Sato K; Ohmine K; Kanda Y
    Intern Med; 2022 Nov; 61(21):3271-3275. PubMed ID: 35370238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
    Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
    Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST.
    Ondecker J; Kordic G; Jordan K
    BMJ Case Rep; 2018 Nov; 11(1):. PubMed ID: 30567109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
    Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Lysis Syndrome.
    Barbar T; Jaffer Sathick I
    Adv Chronic Kidney Dis; 2021 Sep; 28(5):438-446.e1. PubMed ID: 35190110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor lysis syndrome: risk factors, diagnosis, and management.
    Burns RA; Topoz I; Reynolds SL
    Pediatr Emerg Care; 2014 Aug; 30(8):571-6; quiz 577-9. PubMed ID: 25098804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Secondary hyperuricemia in hematologic disease].
    Inai K; Tsutani H
    Nihon Rinsho; 2003 Jan; 61 Suppl 1():299-303. PubMed ID: 12629735
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumour lysis syndrome in haematological malignancies.
    van der Hoven B; Thunnissen PL; Sizoo W
    Neth J Med; 1992 Feb; 40(1-2):31-5. PubMed ID: 1579184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of pediatric tumor lysis syndrome.
    Tazi I; Nafl H; Elhoudzi J; Mahmal L; Harif M
    Arab J Nephrol Transplant; 2011 Sep; 4(3):147-54. PubMed ID: 22026339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour lysis syndrome in solid tumours.
    Gemici C
    Clin Oncol (R Coll Radiol); 2006 Dec; 18(10):773-80. PubMed ID: 17168213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.